News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2011
-
Dec 22, 2011
Antiemetic Agent, Kytril®, Obtained Approval for Additional Indication
[PDF 183KB] -
Dec 20, 2011
Supplemental Biologics License Application Submitted to FDA for ACTEMRA®,
a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
Regarding Adult Rheumatoid Arthritis Indication
[PDF 181KB] -
Dec 19, 2011
Personnel Strategy toward Becoming
A “Top Japanese Pharmaceutical Company”
[PDF 502KB] -
Dec 15, 2011
Chugai to Establish
“Chugai Pharmabody Research Pte. Ltd.” in Singapore,
a New Company for Generating New Antibody Drugs
[PDF 181KB] -
Dec 14, 2011
Bisphosphonate Antiresorptive Agent,
Ibandronate Sodium Hydrate Injection,
Demonstrates Efficacy in Osteoporosis in Phase II/III Trial
[PDF 21KB] -
Dec 14, 2011
Announcing Change of Parent Company and Largest Shareholder (Principal Shareholder)
[PDF 104KB] -
Dec 06, 2011
Personnel Changes
[PDF 37KB] -
Nov 28, 2011
Introduction of iPad2 to Activities for Providing Information to Medical Professionals
[PDF 182KB] -
Nov 25, 2011
Anti-Cancer Agent, Herceptin®
Obtained Approval for Additional Indication and Dosage and Administration
[PDF 176KB] -
Nov 01, 2011
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDF 43KB] -
Nov 01, 2011
Contribution of Para-transit Vehicles to Welfare Services
[PDF 108KB] -
Oct 13, 2011
F. Hoffmann-La Roche Announces Third Quarter Sales 2011
[PDF 16KB] -
Oct 06, 2011
Chugai Presents an Anti-Cancer Charity "Medicine and Humor 2011"
[PDF 199KB] -
Sep 30, 2011
Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin®
for Chemotherapy-Induced Anemia
[PDF 96KB] -
Sep 26, 2011
Anti-Cancer Agent, Avastin®
Obtained Approval for Additional Indication and Dosage and Administration of
“Inoperable or Recurrent Breast Cancer“
[PDF 175KB] -
Sep 26, 2011
Peginterferon alfa-2a “Pegasys®”
Approved for Additional Indication of “Chronic Active Hepatitis B”
[PDF 187KB] -
Sep 16, 2011
Immunosuppressive Agent, CellCept® Obtains Approval for Additional Pediatric
Dosage and Administration for Prophylaxis of Organ Rejection in Renal Transplants
[PDF 201KB] -
Sep 08, 2011
Chugai Establishes Endowed Course at Waseda University
– Focus on Japan’s Leading Cause of Death: Cancer –
[PDF 68KB] -
Sep 02, 2011
Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds
Utilizing the Personalized Healthcare Strategy
[PDF 212KB] -
Aug 19, 2011
Detection of Radioactive Material from RDF Incineration Ashes
at Chugai’s Fuji-Gotemba Research Laboratories
[PDF 189KB] -
Aug 15, 2011
Chugai to In-license BRAF Inhibitor Vemurafenib
[PDF 176KB] -
Aug 10, 2011
Antiemetic Agent, Kytril®
Filed for Additional Indication By
"Application Based on Evidence in the Public Domain"
[PDF 171KB] -
Aug 08, 2011
Organizational and Personnel Changes
[PDF 224KB] -
Aug 03, 2011
Roche's RoACTEMRA Approved in Europe for
Children Living with a Rare and Severe Form of Arthritis
[PDF 160KB] -
Jul 21, 2011
Differences between Consolidated Financial Outlook and Actual Results of Half Year ended June 30, 2011, and Revision of Consolidated Financial Outlook for Fiscal Year 2011 ending December 31, 2011
[PDF 72KB] -
Jul 21, 2011
F. Hoffmann-La Roche Announces 2011 Half Year Results
[PDF 21KB] -
Jul 19, 2011
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®"
Subcutaneous Injection Demonstrates Efficacy
in Rheumatoid Arthritis in Phase III Clinical Study
[PDF 42KB] -
Jul 19, 2011
Chugai Launches a Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe”
[PDF 371KB] -
Jul 15, 2011
New Drug Application Filed for
Recombinant Human Deoxyribonuclease I (rhDNase) "Pulmozyme"
[PDF 239KB] -
Jul 13, 2011
Update on the Impact of the Great East Japan Earthquake
[PDF 22KB] -
Jul 05, 2011
Roche Returns Development and Marketing Rights of SGLT2 Inhibitor “CSG452”to Chugai
[PDF 16KB] -
Jul 01, 2011
Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of
“Pancreatic Cancer Not Amenable to Curative Resection“
and Measures for Proper Use
[PDF 237KB] -
Jul 01, 2011
Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of
Compensated Liver Cirrhosis Related to Hepatitis C
[PDF 282KB] -
Jun 14, 2011
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDF 50KB] -
Jun 13, 2011
Update on the Application of Epogin® in Chemotherapy-Induced Anemia
[PDF 103KB] -
May 27, 2011
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 79KB] -
May 26, 2011
RoActemra Could Change the Current Standard of Treatment for
People Living with Rheumatoid Arthritis
[PDF 193KB] -
May 23, 2011
RoActemra Offers a New Option for
Children Living with a Rare and Severe Form of Arthritis
[PDF 65KB] -
May 16, 2011
Immunosuppressive Agent, CellCept® Filed for Pediatric Dosage and
Administration for Prevention of Organ Rejection in Renal Transplant
by “Application Based on Evidence in the Public Domain”
[PDF 179KB] -
May 09, 2011
Anti-Cancer Agent, Herceptin®
Filed for Additional Indication, and Dosage and Administration
By "New Drug Application Based on Evidence in the Public Domain"
[PDF 168KB] -
Apr 22, 2011
Long-Acting Erythropoiesis Stimulating Agent,
“Mircera® Injection Syringe,” Approved in Japan
[PDF 186KB] -
Apr 21, 2011
Revision of Financial Outlook for Fiscal Year 2011
(January 1 – December 31, 2011)
[PDF 21KB] -
Apr 20, 2011
Chronic Hepatitis C Treatment, Pegasys®, Designated for Priority Review
by Ministry of Health, Labour and Welfare for the Indication of Chronic Hepatitis B
[PDF 173KB] -
Apr 18, 2011
FDA Approves ACTEMRA for the Treatment of
Systemic Juvenile Idiopathic Arthritis (SJIA)
[PDF 159KB] -
Apr 14, 2011
F. Hoffmann-La Roche Announces First Quarter Sales 2011
[PDF 63KB] -
Apr 08, 2011
Launch of the Osteoporosis Agent “Edirol® Capsule”
[PDF 204KB] -
Apr 04, 2011
Impact of the Great East Japan Earthquake (No.3)
[PDF 17KB] -
Mar 23, 2011
Donation of "Tamiflu®" Anti-influenza Drug for the Support of
the Sufferers of the 2011 Off the Pacific Coast of Tohoku Earthquake
[PDF 188KB] -
Mar 18, 2011
Impact of the 2011 off the Pacific coast of Tohoku Earthquake (No.2)
[PDF 36KB] -
Mar 14, 2011
Impact of the 2011 off the Pacific coast of Tohoku Earthquake
[PDF 37KB] -
Mar 14, 2011
Relief Efforts Support for the Disaster Area
Struck by the 2011 Off the Pacific Coast of Tohoku Earthquake
[PDF 167KB] -
Mar 10, 2011
Anti-Cancer Agent, Herceptin®
Obtained Approval for Additional Indication of Advanced or Recurrent
Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection
[PDF 175KB] -
Feb 23, 2011
Anti-Cancer Agent, Xeloda® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection
[PDF 172KB] -
Feb 02, 2011
Notice Regarding Dividend
[PDF 60KB] -
Feb 02, 2011
Information about Appointment of a New Accounting Auditor
[PDF 75KB] -
Feb 02, 2011
Personnel Changes
[PDF 51KB] -
Feb 02, 2011
Organizational and Personnel Changes
[PDF 214KB] -
Feb 02, 2011
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2010
[PDF 67KB] -
Feb 01, 2011
Pegasys ®, and Copegus ®, Designated for Priority Review by MHLW
for the Indication of Compensated Liver Cirrhosis Related to Hepatitis C
[PDF 181KB] -
Jan 27, 2011
Chronic Hepatitis C Treatment, Pegasys®,
Filed for Additional Indication of Chronic Hepatitis B
[PDF 173KB] -
Jan 24, 2011
Chugai Launches A New Disease Awareness Website for Rheumatoid Arthritis
- “Heidi, a Girl of the Alps” navigates through the website - [PDF 278KB] -
Jan 21, 2011
An Active Vitamin D3 Derivative “Edirol®,” Approved in Japan
[PDF 27KB] -
Jan 06, 2011
FDA Grants Supplemental Approval for ACTEMRA
[PDF 107KB]
